Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen-Reference-Cited by-同舟云学术

Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen

Published:2008-09-12 Issue:14 Volume:22 Page:1809-1813
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Delaugerre Constance,Pavie Juliette,Palmer Pierre,Ghosn Jade,Blanche Stephane,Roudiere Laurent,Dominguez Stephanie,Mortier Emmanuel,Molina Jean-Michel,de Truchis Pierre

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference15 articles.

1. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir;Molla;Nat Med,1996

2. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates;De Meyer;Antimicrob Agents Chemother,2005

3. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier;Dierynck;J Virol,2007

4. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials;Clotet;Lancet,2007

5. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3;Molina;J Acquir Immune Defic Syndr,2007

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges;Current Topics in Medicinal Chemistry;2019-10-09

2. Molecular Determinants of Epistasis in HIV-1 Protease: Elucidating the Interdependence of L89V and L90M Mutations in Resistance;Biochemistry;2019-08-06

3. Novel Protease Inhibitors Containing C-5-Modified bis -Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2′ Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance;Antimicrobial Agents and Chemotherapy;2019-08

4. Consistent Prediction of Mutation Effect on Drug Binding in HIV-1 Protease Using Alchemical Calculations;Journal of Chemical Theory and Computation;2018-05-30

5. Mechanism of Darunavir (DRV)’s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance;mBio;2018-05-02